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Hematopoietic stem cell transplantation is standard therapy for numerous hematological 
diseases. The use of haploidentical donors, sharing half of the HLA alleles with the 
recipient, has facilitated the use of this procedure as patients can rely on availability 
of a haploidentical donor within their family. Since HLA disparity increases the risk of 
graft-versus-host disease, T-cell depletion has been used to remove alloreactive lympho-
cytes from the graft. Selective removal of αβ T cells, which encompass the alloreactive 
repertoire, combined with removal of B cells to prevent EBV-related lymphoproliferative 
disease, proved safe and effective in clinical studies. Depleted αβ T cells and B cells are 
generally discarded as by-products. Considering the possible use of donor T cells for 
donor lymphocyte infusions or for generation of pathogen-specific T cells as mediators 
of graft-versus-infection effect, we tested whether cells in the discarded fractions were 
functionally intact. Response to alloantigens and to viral antigens comparable to that of 
unmanipulated cells indicated a functional integrity of αβ T cells, in spite of the manip-
ulation used for their depletion. Furthermore, B cells proved to be efficient antigen-pre-
senting cells, indicating that antigen uptake, processing, and presentation were fully 
preserved. Therefore, we propose that separated αβ T lymphocytes could be employed 
for obtaining pathogen-specific T cells, applying available methods for positive selection, 
which eventually leads to indirect allodepletion. In addition, these functional T cells could 
undergo additional manipulation, such as direct allodepletion or genetic modification.
Keywords: hla-haploidentical transplantation, graft manipulation, αβ T  cells, alloreactivity, antigen-induced 
activation, B-cell presentation
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inTrODUcTiOn
HLA-haploidentical hematopoietic stem cell transplantation 
(haplo-HSCT) from a related donor is a suitable option for 
patients affected by many malignant and non-malignant hema-
tological diseases (1–3). In fact, patients have a high chance of 
having a haploidentical related donor within their family group, 
and pediatric patients, in particular, can rely on both parents 
as potential donors. Nevertheless, due to the incompatible 
haplotype, the risk of graft-versus-host disease (GvHD) is high 
in haplo-HSCT (2). Removal of T cells encompassing the allo-
reactive precursors has been applied to prevent GvHD (4, 5), as 
recently reviewed (6). This procedure is effective in preventing 
GvHD, but a concomitant increase of graft rejection (7, 8), loss of 
T-cell mediated graft-versus-leukemia (GvL) effect, with higher 
incidence of relapse of the primary malignant disease (9–12), 
and loss of graft-versus-infection (GvI) effect, with a higher risk 
of severe opportunistic infections due to delayed reconstitution 
of pathogen-specific T-cell immunity (13–15), have been also 
observed. In comparison to a bone marrow-derived graft, the 
introduction of G-CSF-mobilized HSC (16) made the apher-
etic product a more convenient cell source for haplo-HSCT. 
Recently, more selective procedures of graft manipulation have 
been introduced to remove alloreactive precursors within well-
defined T-cell subsets, preserving other mononuclear cells that 
exert protective immune functions. Selective T-cell depletion can 
include (i) removal of αβ T cells, which encompass the alloreac-
tive precursors, sparing γδ T cells, and natural killer (NK) cells, 
which play a protective role against opportunistic infection and 
regrowth of leukemia cells (17) and (ii) removal of the CD45RA 
naïve T-cell fraction containing alloreactive precursors, sparing 
the memory fraction containing T cells responsive to opportun-
istic pathogens (18–20). The first procedure, based on removal of 
αβ T cells with anti αβ TCR antibodies bound on paramagnetic 
microbeads, which are retained by a magnetic column, is now 
commercially available with certified reagents, protocols, and 
automated instrumentation (Miltenyi Biotec, Bergish Gladbach, 
Germany). This procedure includes concomitant removal of 
B cells with anti-CD19 antibodies with the purpose of reducing 
the risk of EBV-associated posttransplant lymphoproliferative 
disease. Clinical results demonstrating the safety and efficacy of 
this procedure have been recently reported (21–23).
The αβ T-cell and B-cell depleted product (graft) contains, in 
addition to CD34 HSC, other mononuclear cells such as NK cells, 
γδ T cells, and monocytes/dendritic cells (MoDC), which exert 
positive immune functions (21). The labeled αβ T cells and B cells 
retained by the magnetic column represent the non-target (NT) 
population. If the magnetic field is withdrawn from the paramag-
netic column, the retained cells can be eluted and collected as the 
NT fraction, but they are generally disposed of.
We considered the NT fractions as an immunological asset 
worth analyzing for specific functions after the in  vitro graft 
manipulation. NT cells, in fact, could be considered as an alter-
native source of T  cells for unmanipulated donor lymphocyte 
infusion (DLI) to control/prevent infectious complications 
(GvI effect) or to prevent/treat relapse of the primary malig-
nancy (GvL  effect) (24–27). Additionally, NT  cells can be a 
valuable starting material to obtain antigen-specific T cells able 
to accelerate immune reconstitution (28), by using direct selec-
tion procedures based on multimer technology as described on 
recent reports (29–31). These reports are of special relevance in 
this context as they demonstrate that low doses of selected T cells 
effectively provided a GvI effect and could expand in  vivo to 
reconstitute a protective T-cell response. Furthermore, the same 
T  cells can be considered for further advanced manipulation 
(32–35) for the introduction of suicide genes or for expression of 
novel engineered T-cell receptors.
In light of these considerations, in this work we tested the 
preservation of antigen-specific functions of αβ T cells and the 
antigen-presenting function of B cells present in the NT fraction 
after the depletion procedures.
MaTerials anD MeThODs
reagents and Media
The kit for αβ T-cell/B-cell depletion includes reagents and 
disposable bags with interconnecting tubing in addition to 
the in-line magnetic column (Miltenyi, Bergish Gladbach, 
Germany). The PBS-EDTA buffer (Miltenyi) was supplemented 
with human serum albumin (HSA, Grifols, Barcelona, Spain). 
Ficoll (Lymphoprep) was obtained from Sigma (St. Louis, MO, 
USA). RPMI 1640 with HEPES buffer, l-glutamine, and antibiot-
ics were from Euroclone (Milan, Italy). PPD was purchased from 
Statens Seruminstitut (Copenhagen, Denmark). CMV, EBV, and 
adenovirus antigens were obtained from Microbix Biosystems 
(Mississauga, ON, Canada) as lysates of infected cells centrifuged 
to remove cell debris. The CMV pp65 peptide library (pepmix, 
15mer peptides overlapping by 11 residues) was purchased from 
JPT (Berlin, Germany). Reagents for IFNγ ELISA were from 
Mabtech (Stockholm, Sweden) and 3H-thymidine (specific activ-
ity 0.25 TBq/mmole) was from Perkin Elmer (Boston, MA, USA). 
Monoclonal antibodies (Moab) for cell phenotyping were from 
Becton Dickinson (San Josè, CA, USA), and they were used in 
combinations previously described (36).
collection of nT cells
Donors of cells for haplo-HSCT underwent an apheretic session 
after HSC mobilization with G-CSF (22, 36). The cells in the apher-
esis (Aph) bag were processed to remove αβ T cells and B cells, as 
described in Ref. (37), following the detailed protocol provided 
by Miltenyi. Briefly, cells in the Aph bag were tagged with biotin-
conjugated anti-αβ TCR Moab. After incubation and washing, 
the cells were labeled with paramagnetic beads conjugated to 
anti-biotin and anti-CD19 antibodies. After washing to remove 
unbound beads, the cell suspension was loaded on the CliniMACS 
device to automatically process cells through a magnetic column, 
which retains the labeled cells (αβ T cells and CD19 B cells). The 
effluent cells in the collection bag (CB) included CD34 HSC, 
hematopoietic precursors, γδ T cells, NK cells, MoDC, and repre-
sented the graft ready for infusion into the recipients. The average 
performance of 200 procedures, evaluated as depletion efficiency 
of unwanted cells and as recovery efficiency of desired cells (38), 
matched the data from other reports (22, 36, 37, 39). The retained 
TaBle 1 | hla typing and viral serological status of the 20 donors 
included in the study.
Donor # hla typing serology
a B c Dr cMV eBV adV
1 30, 1 35, 37 4, 6 4, 15 + + +
2 31, 11 35, 51 4, 7 1 + + +
3 23, 24 49, 27 7, 15 1, 11 + + +
4 3 35, 53 15, 4 8, 13 + + −
5 24, 1 51, 37 16, 6 13, 11 + − +
6 24, 2 44, 27 7, 2 4, 3 + + +
7 2, 32 44 7, 5 4, 4 + + +
8 30, 11 13, 15 6, 4 7, 13 + − −
9 2, 29 13, 39 4, 6 4, 4 + + +
10 2, 26 14, 55 3, 8 1, 13 + − +
11 11, 3 18, 14 7, 8 14, 13 + + nt
12 2 39, 13 12, 6 16, 7 + + +
13 1, 31 44, 51 7, 15 7, 4 + + +
14 24, 31 44, 51 2, 15 4, 15 + + +
15 1, 2 8, 57 7 3, 7 + + +
16 24, 11 35, 15 4, 1 11, 7 + + +
17 30, 23 14, 7 8, 7 10, 11 + − +
18 1, 68 35, 18 7, 7 1, 11 + − +
19 22, 23 38, 41 12, 17 13, 7 + + +
20 11, 2 35, 51 4, 15 4, 4 − + +
Positive serological status was defined according to thresholds provided by the clinical 
laboratory.
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population, consisting of αβ T cells and B cells, was designated as 
the NT fraction. This fraction could be eluted from the column 
upon withdrawal of the magnetic field. Samples from the different 
fractions obtained from 20 depletion procedures performed on 
20 donors were saved for the experiments described here. HLA 
typing and serostatus of the donors is reported in Table 1. Positive 
serostatus was defined according to thresholds provided by the 
clinical laboratory.
Processing of nT cells
Samples were obtained from the Aph bag, from the CB, and from 
the NT fraction. Cells were used for phenotypic characterization to 
evaluate procedure efficiency and for testing functional activity, as 
described here. Cells were kept in PBS–EDTA–HSA 0.5% buffer at 
4°C for up to 24 h before processing. After washing with PBS, cells 
were loaded on conventional Ficoll gradients to obtain the mono-
nuclear fraction. This step was not required for NT fractions, which 
already contained purified αβ T cells and B cells, but at any rate it was 
used for better parallel comparison with the other cell fractions. Ficoll 
passage and washing of the NT fractions removed the residual free 
beads that were eluted from the column along with labeled cells. Cells 
were resuspended at 2 × 106 cells/ml in RPMI 1640 medium sup-
plemented with l-glutamine 2 mM, 2-mercapto-ethanol 5 × 10−5 M, 
penicillin 100 U/ml, and streptomycin 100 μg/ml. Heat-inactivated 
human AB serum (Sigma) was added at 5% final concentration to 
produce the complete medium. Average cell viability was >90%.
Functional assays for antigen-specific 
responses
Allospecific responses against T-cell depleted allogeneic PBMC 
from random donors as stimulator cells were tested in one-way 
mixed lymphocyte reactions (MLR). T-cell depletion was per-
formed using anti-CD3 magnetic beads (Dynal, Thermo Fisher) 
following the manufacturer’s instructions. T-depleted stimulator 
cells from four subjects were pooled and frozen in aliquots as an 
allo-pool in order to maximize responder versus stimulator HLA 
disparity. When needed, cells were thawed, washed, and irradi-
ated (30 Gy) before use. Responder cells were seeded at 100 μl/
well (2 × 105 cells) with an equal number of stimulator cells in 
100 μl in 96-well, flat bottom microtiter plates. Responses were 
tested as IFNγ secretion after 2-day incubation. ELISA assays 
were run on culture supernatants following manufacturer’s 
instructions. Results are given as picogram per milliliters IFNγ or 
as stimulation indexes (SI, picogram per milliliters with antigen: 
picogram per milliliters background). A positive alloresponse 
was defined as having an SI ≥ 10. Responses to soluble antigens 
were tested on 2 × 105 cells in 200 μl medium. Specific antigens 
included CMV, EBV, adenovirus lysates, CMV pp65 peptide 
mix, and PPD. Antigens were used at 5 μg/ml final concentra-
tion. After 5-day incubation, cultures were pulsed with 18 kBq 
3H-thymidine for 18 h and harvested on glass fiber filters. Dry 
filters were counted on a Microbeta Trilux 1450 counter (Wallac, 
Perkin Elmer). Results are expressed as SI (cpm with antigen/
cpm background). An SI ≥ 3 defined an antigen-specific positive 
response.
Statistical analyses were performed using the Graph Pad 
Prism 6.1 version software. Significant differences between sets 
of data were determined by the Mann–Whitney test. Correlation 
between paired data sets was determined using the Pearson’s coef-
ficient. Highly significant differences were defined by p < 0.01.
resUlTs
Depletion efficiency and enrichment of αβ 
T and B cells
Figure 1 shows the composition of the manipulated cell fractions 
in 20 different procedures from which samples were obtained 
for this study. Most CD34 HSC, NK  cells, and γδ T  cells were 
recovered in the CB fractions. A remarkable depletion was 
achieved for αβ T cells and B cells, with mean values of around 
12,000 × 106 and 3,000 × 106 in the Aph samples versus 1 × 106 
and 0.8 × 106 in the CB fractions. These cell subsets were recov-
ered in the NT fractions, with mean values of around 10,000 × 106 
and 2,800 × 106, corresponding to a recovery efficiency of 84 and 
93%, respectively. Since these figures obtained from 20 proce-
dures overlap with the results obtained from over 200 procedures 
performed in our laboratory (38), the data reported below can be 
considered fully representative of the fractions obtained with the 
standard depletion procedure. In order to better visualize the αβ 
T- and B-cell depletion from the CB fractions and their recovery 
in the NT fractions, the graphs in Figure 1B express the results 
as relative percentages.
Preservation of T-cell alloreactive 
responses
Representative examples of MLR are shown in Figure  2. 
Alloreactive responses were tested in Aph samples and in NT 
FigUre 1 | composition of cellular fractions obtained from αβ T-cell/B-cell depletion procedures. Twenty depletion procedures were used for the reported 
experiments. Samples of the different cell fractions—apheresis (Aph), collection bag (CB), and non-target (NT) fraction—were evaluated for cellular composition. 
Dark gray bars indicate αβ T cells and B cells, while light gray bars refer to the other subsets. Results are shown as mean values ± SD of total cell numbers for each 
subset on a log scale in panel (a). Relative frequency of the same subsets is shown in panel (B) as percentages of the total NC identified by flow cytometry. The 
Mann–Whitney test was used to define non-significant differences in αβ T-cell and B-cell numbers (a) or frequencies (B) between Aph and NT samples, indicating 
full recovery of the depleted cells in the NT fractions. By contrast, highly significant depletion for αβ T cells and B cells can be observed in panels (a,B) by comparing 
the Aph and the CB samples.
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samples. Upper panels show results as IFNγ concentration, while 
middle panels show results as SI. It should be noted that IFNγ 
concentrations have been normalized and referred to 105 αβ 
T cells for each donor to take into account the fact that different 
numbers of αβ T cells were present in the Aph and in the NT 
fractions. The two graphs on the left are examples of concordant 
responses, with high alloreactivity in both Aph and NT  cells. 
The two graphs on the right provide examples of discordant 
responses. The bottom plot shows responses of Aph and of 
NT cells for each tested donor. Assuming a threshold of SI ≥ 10 
for a positive alloresponse, 7/7 NT fractions were positive, 
while 3/7 Aph samples were positive. No opposite cases of NT 
negative and Aph positive alloresponses were observed. Overall 
correlation between alloresponses in NT and in Aph fractions 
was not statistically significant.
Maintenance of specific T-cell response 
to Protein antigens
Since we did not know whether B  cells in the NT fractions 
had reduced APC function due to a possible interference with 
this function by anti-CD19 beads bound to the cell surface or 
because of extensive manipulation, we added irradiated cells 
from the CB fractions (CB*), which contain professional APC 
represented by MoDC, to ensure an adequate APC function. 
Four representative examples of antigen-specific responses 
expressed as SI are shown in Figure  3, upper panels. Lower 
FigUre 2 | analysis of alloreactive responses. The upper panels show IFNγ concentration as picogram per milliliters measured by ELISA on culture 
supernatants from mixed lymphocyte reaction assays (+, allogeneic stimulator cell pool; −, autologous control cells). The IFNγ concentrations have been normalized 
and referred to 105 αβ T cells for each donor, considering that these cells were present at different concentrations in the Aph and in the non-target (NT) fractions. 
The middle panels show the corresponding stimulation indexes (SI). Four representative donors are shown, with vigorous responses in both Aph and NT samples in 
the two left hand panels and vigorous responses in the NT fractions only in the two right hand panels. The bottom panel shows a summary plot of SI for Aph and NT 
samples for each donor, with no statistically significant correlation between the paired data (Pearson’s coefficient test). Dashed lines indicate SI = 10.
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panels (Figures 3A–E) illustrate the response for each antigen 
in the Aph fractions and in the NT (+CB*) fractions for all 
donors. A positive response to one or more antigens seen in NT 
fractions suggested that αβ T cells were not impaired in their 
specific capacity to recognize antigens. A summary of responses 
to the various antigens is shown in Figure 3F. A possible asso-
ciation between serostatus and T-cell response to viral antigens 
was considered by defining the frequency of concordant 
responses, either positive or negative. The seropositive status 
defined using the threshold provided the clinical laboratory and 
the positive T-cell response was defined by SI ≥ 3 in Aph and/or 
NT fractions. Concordance was 84% for CMV responses, 89% 
for EBV responses, and 47% for AdV responses. This suggests 
that T-cell responses should be defined independently of the 
donor’s serostatus.
ability of B cells to Process and 
Present Protein and Peptide antigens to 
specific T cells
After demonstrating that αβ T  cells in the NT fractions are 
functionally intact, we evaluated whether B cells present in the 
same fractions were capable of exerting their APC function or 
whether additional professional APC, such MoDC present in 
the CB fractions, were necessary for optimal T-cell activation. 
By using protein antigens, such as viral lysates in addition to the 
CMV pp65 peptide mixture, it was possible to test the antigen 
uptake and processing ability and not simply the APC func-
tion of B  cells. Figure  4 demonstrates that MoDC in the CB 
fractions irradiated at 30 Gy, which abolishes the function of 
residual T cells but preserves the function of APC, were of no 
FigUre 3 | responses to soluble antigens. The upper panels show representative lymphoproliferation assays of Aph and non-target (NT) (+irradiated CB*) 
samples from four donors stimulated with the following antigens: PPD, CMV lysate, CMV pp65 pepmix, EBV lysate, and AdV lysate. Different response profiles are 
shown. Responses to PPD, CMV lysate, CMV pp65 pepmix, EBV lysate, and AdV lysate in 20 pairs of Aph and NT (+CB*) samples are shown in the lower panels 
(a–e) as dot plots. A comprehensive view of responses to all antigens is given in panel (F). Results are shown as stimulation indexes (SI). Dashed lines indicate 
SI = 3. Responses with identical SI in the two fractions overlap in the same position, and thus fewer than 20 dots may appear. A statistically significant correlation 
could not be established between Aph and NT (+CB*) responses (Pearson’s coefficient test).
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advantage when added as supplementary APC and, on certain 
occasions, were even detrimental to specific T-cell responses. 
This is shown in Figures 4A–D, in which all data are reported 
for each antigen. It appears that B  cells contained in the NT 
fractions were fully functional as APC and required no addi-
tional support. The overall superior responsiveness of NT cells 
alone is evident also from Figure 4E, in which SI for all antigens 
have been plotted.
comparison of response in aph and in 
nT samples
For a better evaluation of the discrepancies between NT and Aph 
responses observed on several occasions, Figure 5 shows the per-
cent positive responses defined by an SI ≥ 3 to each tested antigen 
in all Aph samples and NT samples. The highest frequency of 
positive responses in Aph and/or NT samples was seen with CMV 
(55% for Aph and 60% for NT), while the lowest frequency was 
observed for AdV (24% for Aph and 16% for NT).
DiscUssiOn
Recovery of antigen-specific T  cells from G-CSF mobilized 
aphereses has been the subject of some conflicting reports. 
While G-CSF can increase the number of circulating lym-
phocytes (40–42), the observation that G-CSF inhibits the 
production of Th1-type cytokines raised concerns on the use 
of mobilized T  cells with respect to immune reconstitution 
(43–47). Nevertheless, T  cells from mobilized donors proved 
suitable for specific selection using either multimers (48, 49) or 
activation markers for enrichment and expansion (50, 51), with 
effectiveness comparable to that of T cells from non-mobilized 
samples.
In the perspective of selecting virus-specific T cells from NT 
fractions, we need to discuss several aspects related to the isola-
tion procedure. Basically, two approaches are to be considered, 
one based on multimer selection and one based on selection with 
the cytokine secretion system (CSS).
In the first case, the multimer technology, initially described 
in Ref. (52), was successfully applied for selection and reinfusion 
of virus-specific T cells (53, 54). Nevertheless, the introduction 
of reversible streptamers, which can be eluted from the selected 
T  cells (55), allowed more studies to demonstrate that T  cells 
isolated with these reagents are functionally superior to CTL 
lines with the same CMV specificity in terms of protective 
potential (56), provide better protection when expressing high 
avidity TCR (57), have a remarkable proliferative capacity after 
infusion (29), can be serially transferred between experimental 
animals thanks to their stemness (30), and do not need to be 
specific for immunodominant epitopes (58). Finally, specific 
T  cells can be isolated with minimal manipulation as cellular 
products for clinical use (31). Therefore, streptamer-enriched 
T cells can be proposed for immune reconstitution (59), as well 
as for immunotherapy of selected tumors (59, 60). A variation on 
the theme of reversible streptamers was introduced to dissociate 
FigUre 5 | Frequency of antigen-specific responses in paired 
samples. Positive responses to soluble antigens defined by stimulation 
indexes (SI) ≥3 are shown by bars referring to Aph (light gray) and to 
non-target (NT) (dark gray) samples.
FigUre 4 | ability of B cells to present soluble antigens to specific T cells. Responses to various antigens by 20 pairs of non-target (NT) (+irradiated CB*) 
and NT samples are shown in panels (a–D) as dot plots. Responses with identical stimulation indexes (SI) in the two fractions overlap in the same position, and thus 
fewer than 20 dots may appear. Dashed lines indicate SI = 3. Responses to all antigens are summarized in panel (e), showing that responses by NT cells are more 
vigorous than responses by NT (+CB*) cells. A statistically significant correlation could not be established between Aph and NT (+CB*) responses (Pearson’s 
coefficient test).
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multimers from CMV-specific selected cells by coupling onto 
cobalt-based magnetic beads histidine-tagged MHC molecules, 
which monomerize in the presence of histidine as specific 
inhibitor (61).
In the second case, the CSS, described in Ref. (62, 63), was 
applied for selection of CMV-specific T cells in in vitro studies 
(64, 65). In vivo studies demonstrated successful immune recon-
stitution with T cells specific for CMV (66), adenovirus (67), and 
EBV (68, 69).
Both these approaches are appealing as they allow positive 
selection of specific and functional T  cells in a period of time 
much shorter than that needed to generate after rounds of antigen 
stimulation-specific T-cell lines, as it has been used in the past 
(70–72). We should keep in mind that multimers allow selection to 
be performed in a few hours with a simple procedure, without the 
requirement of an activation step, but they can be used only with 
selected epitopes on a limited array of HLA alleles and mostly for 
selection of CD8 T cells. In contrast, the CSS procedure requires 
an activation phase and more complex steps of cell processing, 
but it can activate both CD4 and CD8 cells simultaneously, is not 
limited by the available recombinant HLA alleles, and mixtures of 
peptides from different proteins and viruses can be used.
The use of multimer-selected CMV-specific T  cells for 
immune reconstitution has been described in the past (53, 
54), proving to be a rapid and highly effective procedure. This 
approach has been recently reviewed and advocated (73), but 
some limitations, intrinsic in the multimer strategy, should be 
considered. Multimer selection for immune reconstitution is 
limited to CD8 CTL and restricted to the HLA alleles avail-
able at present for multimer construction. Immunodominant 
epitopes must be known for each pathogen, and different 
multimers must be constructed with each peptide and each 
HLA allele. These aspects also apply to multimer-based selec-
tion of specific T cells from G-CSF mobilized aphereses (48). 
In addition, multimer-selected T cells from mobilized samples 
showed a reduction of antiviral function when compared to 
non-mobilized products (49).
Several conclusions can be drawn from the experiments 
presented in our study. First, antigen-specific responses by 
αβ T cells in the NT fractions were well preserved, in spite of 
manipulation steps, which included labeling, washing, column 
passage, and elution. In several cases, responses by NT cells were 
even higher than those obtained with unprocessed T cells from 
the Aph fractions. Second, antigen processing and presenting 
capacity was exerted by B cells in full, as additional APC, such 
as MoDC from the CB population, did not increase specific 
T-cell responses. The preserved T-cell function indicates that 
anti-αβ TCR–bead complexes on T cells did not interfere with 
cell functions (antigen recognition, proliferation, and cytokine 
secretion), as demonstrated by vigorous responses of NT cells 
in comparison with unmanipulated Aph cells. To explain this 
observation, we propose that only a fraction of TCR molecules 
are engaged by anti αβ TCR Mab on the cell surface or that 
antibody–bead complexes are rapidly internalized after cell 
incubation in culture (Miltenyi, personal communication). 
Similar to the T-cell hypothesis, anti-CD19–bead complexes on 
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B cells, even if persisting on the cell surface, did not interfere 
with antigen uptake, processing, and presentation, suggesting 
that either engagement of CD19 does not affect the APC func-
tion or not all CD19 molecules are bound or complexes are 
promptly recycled from the B cell surface as an active process 
during cell incubation.
With these considerations in mind, preservation of T-cell 
function suggests that the discarded NT fractions could be con-
sidered as an alternative product for DLI, saving the donor the 
cost and the discomfort of a new apheretic session. In particular, 
in case a second Aph cannot be performed for whatever reason, 
NT cells represent a feasible alternative.
A mean number of 1010 αβ T cells were present in the NT frac-
tions. This number largely exceeds the number of T cells theoreti-
cally encompassing a full human repertoire (74, 75). In particular, 
memory T  cells, which represent the subset most relevant for 
protection from opportunistic infections, is represented by 
approximately 106 different clonotypes with a frequency of each 
pathogen-specific T cell (including CD4 and CD8 cells) ranging 
between 0.05 and 5% in peripheral blood (76). An alternative 
estimate has been proposed by assessing the diversity of the TCR 
β chains only by high throughput sequencing (74). In this case, 
the diversity of the memory repertoire was calculated at around 
106 different clonotypes, but, considering combinatorial diversity 
contributed by TCR α chains, the figure can be remarkably higher. 
These evaluations imply that each clonal specificity is represented 
by at least one T cell in a sample containing a few million T cells. 
Therefore, the discarded NT fractions contain thousands of cells 
from each memory T-cell clone specific for pathogen antigens, 
redundantly reflecting scores of replicates of the same memory 
repertoire. Even if far from being accurate, these figures underline 
how valuable the NT fractions can be from an immunological 
point of view.
With respect to the observation that specific responses were 
occasionally higher in NT cells than in Aph cells (or in NT plus 
CB cells), we should keep in mind that the simplest functional 
unit for cellular immune response is represented by one spe-
cific T cell interacting with one APC. Other neighboring cells 
may interfere with this interaction, and a third party may not 
be welcome. Since NT fractions are enriched in T and B cells, 
antigen-driven cellular interactions may be facilitated. This 
may account for better responses in NT fractions than in Aph 
samples, or than in NT fractions supplemented with CB cells. 
CB fractions, in fact, in addition to MoDC, contain other cell 
types, such as NK  cells and γδ T  cells, which may physically 
interfere with antigen-driven T–B interactions. On the contrary, 
it is hard to explain why we occasionally observed specific 
responses higher in Aph than in NT samples. In this case, it is 
possible that the column elution procedure for NT fractions, 
which follows the collection of CB fractions to be transplanted, 
might occasionally affect T-cell functions in NT samples. The 
observed variability suggests that T-cell functions should be 
checked in each preparation.
In case large numbers of T cells are required, an aliquot from 
the mobilized apheretic donation (48) may not suffice. On the 
other side, a second Aph is hard to propose in case a matched 
unrelated donor is used for the allograft, due to donor or registry 
denial, or it may sometimes not be feasible in the haploidentical 
donor setting for personal or health reasons. Altogether, these 
considerations make the use of NT cells particularly appealing.
Our view on recovered NT cells is not limited to their exploi-
tation as a substitute for DLI. Thanks to their intact functions, 
these cells can be candidates for additional in vitro manipula-
tion before reinfusion. A note of caution should be introduced, 
though, considering that GCSF has been recently shown to 
affect some functions of CD8 T cells, without impairing their 
in vitro expansion (77, 78). In this regard, it will be interesting 
to test whether this effect is reversible upon in vitro culture. Cell 
manipulation may include specific allodepletion, selection, and 
expansion of specific T cells, genetic manipulations to introduce 
suicide genes, or novel chimeric receptors for their retargeting. 
These possibilities, which need to be experimentally validated 
on NT cells, are outlined in Figure 6, with relevant references 
provided in the legend.
With respect to B cells present in the NT fractions, in addition 
to their intact APC function demonstrated here, three functional 
features are being tested in experiments in progress, as illustrated 
in Figure 6. The first one is in vitro expansion with CpG or with 
anti-CD40 antibodies in order to produce large numbers of APC 
to be used in restimulation cycles for the generation and expan-
sion of antigen-specific T-cell lines. The second one is related to 
EBV transformation of these B cells available in large numbers 
for production of lymphoblastoid cell lines (LCL) to be used for 
generation of EBV-specific CTL (86, 87) using a faster approach as 
compared with direct LCL generation from peripheral blood sam-
ples. This may permit generation of EBV-specific CTL lines with a 
procedure swifter than advocated in standard protocols. The third 
one relates to B-cell removal from the T-cell products. In fact, if 
multimers are used for T-cell selection on a magnetic column 
right after the αβ T-cell/B-cell depletion procedure, B cells, which 
are still coated with anti-CD19 magnetic beads, might be retained 
by the magnetic column and copurify together with multimer-
labeled, antigen-specific T cells. Therefore, a preincubation step is 
required to allow internalization and degradation of the magnetic 
beads used for B-cell depletion. In case specific T cells are selected 
with other methods, based on the expression of activation 
markers (76) or on the cytokine capture system (62, 63), prior 
antigen stimulation, which depends on the presenting function 
of B cells, is needed. In this case, beads used for the first depletion 
are internalized and degraded during the incubation phase and 
do not interfere with the second depletion phase. Since specific 
T cells are positively selected, B cells are excluded from the final 
product. On the other side, if T cells are stimulated and repeat-
edly expanded to produce established T-cell lines, B cells present 
among the cells used as APC can be physically removed by negative 
selection with anti-CD19 beads or can be neutralized by previous 
irradiation.
In conclusion, our data are in agreement with other reports 
testing the possible recovery of cellular products obtained after 
manipulation procedures (48–51, 88–90), suggesting that frac-
tions comprising αβ T cells and B cells obtained as by-products 
of ex vivo manipulation (38) of apheretic or bone marrow grafts 
FigUre 6 | continued
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FigUre 6 | continued  
Flow diagram for proposed exploitation of αβ T cells and B cells from non-target (nT) samples using simple or advanced procedures. T cells 
contained in the NT fractions can be used for unmanipulated donor lymphocyte infusion (DLI) (a1) or after B cells have been removed (a2). This can be achieved by 
cell preincubation to allow internalization and degradation of the paramagnetic beads, followed by a depletion step with anti-CD19 beads only. T cells can be 
manipulated to reduce the frequency of alloreactive cells (b) for graft-versus-host disease prevention by using one of the methods already proposed in previous 
studies, as recently reviewed (75). T cells can be polyclonally expanded with anti-CD3 antibodies (c) (33) to produce large numbers of activated cells ready for 
subsequent genetic manipulations, such as introduction of suicide genes, like thymidine kinase (TK) or inducible caspase-9 (iCasp9) (d1) (32, 79), for redirection of 
specificity by introducing a chimeric antigen receptor (d2) (35) or for functional manipulation by adding genes for accessory molecules or cytokines (d3) (35, 80). 
T cells can be selected based on specificity for antigens of relevant pathogens (e) by using several strategies (f). Multimer selection does not require previous antigen 
stimulation in the presence of APC (f1), while selection based on expression of activation markers (f2) or on cytokine capture (f3) does require antigen activation with 
APC. APC can be untreated autologous B cells (j), expanded (k), or modified B cells (l, m). These procedures are followed by positive selection of activated T cells 
usually based on paramagnetic microbeads (g) to select T cells specific for adenovirus (67), CMV (81), or EBV (68). Finally, T cells can be stimulated and expanded 
in vitro to generate established T cell lines specific for antigens of relevant pathogens, using different protocols (h) (31). As an example, peptides and proteins can be 
used in the presence of APC as autologous B cells (i1). EBV-transformed autologous B cells can be used to activate EBV-specific T cells (i2). Genetically modified 
APC can express antigens of different viruses (i3) (82) to obtain multi-virus-specific T-cell lines. On the other side, B cells can be considered adequate APC under 
different conditions. B cells can be used untreated (j) or simply irradiated, terminally expanded in vitro with CpG (83), or long-term expanded with anti-CD40 
antibodies (k) (84, 85). B cells can be transformed with EBV to generate lymphoblastoid cell lines (LCL) (l), which can directly present EBV antigens to T cells or can 
be genetically modified to express new viral antigens (m) (82).
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are a valuable source of cells, which may be useful for adoptive 
immunotherapy after HSCT.
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